DelSiTech in-house product pipeline

DelSiTech develops its own drug products by combining its silica-based drug delivery technology platform with known active substances to produce supergeneric products with superior characteristics over the original brand product.

The first in-house drug product under development is the  product candidate 1308 which is based on an undisclosed active substance. 1308 addresses significant unmet medical  and commercial needs in infectious diseases. The product is currently in late preclinical development and the clinical program is expected to start within 12 months.  

Cell culture plate